The restructuring arrives during a period of turmoil at California-based 23andMe, which has recently included a high-profile ...

No. 23andMe is considered a direct-to-consumer genetic testing company, and transactions with the company are considered commercial, not medical. Because 23andMe is not a medical company, customers' ...

Me announced on Monday it would cut 40% of its workforce, representing more than 200 employees, as part of a restructuring at ...

Wojcicki attempted to take 23andMe private, proposing an official offer to the board of directors in late July. However, the board quickly rejected the offer, and seven independent directors resigned, ...

23andMe's CEO called the decision to lay off 200 employees ... The suffering company faced another blow in September when its board of directors resigned. The board’s seven members quit after Wojcicki ...

In a significant move to stabilize its operations, 23andMe has announced the layoff of 200 employees, representing a ...

Back in September, all of 23andMe’s independent directors also resigned from its board — in a rare move that followed ...

Sales for the Atlanta-based company improved 6.6 percent to $40.22 billion, topping the $39.31 billion that analysts ...

23andMe, a popular South San Francisco-based genetic testing company, is laying off 40% of its workers after struggling with ...

Me is laying off 40% of its workforce right before the holiday season - The restructuring arrives during a period of turmoil ...

Genetics testing company 23andMe is trimming its headcount by 40%. The company said it is undergoing a restructuring to ...